Cutting edge immunotherapies beneficial to cancer patients

Biosyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies.

Our proprietary and advanced CAR-T and TCR-T immunotherapies to fulfill the unmet needs in cancer treatment

Biosyngen is developing first and best-in-class CAR-T and TCR-T cells targeting multiple solid tumors and lymphomas.

Our Pipeline

Biosyngen ongoing clinical trial against nasopharyngeal cancer, gastric cancer and lymphoma in multiple centers, filing Investigational New Drug application with CDE, FDA

cancer
EBV

Headlines

Read the latest updates from Biosyngen.

Let's Talk

We revolutionise and transform innovative technologies

en_USEN